<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

 

Hepatocellular Carcinoma (HCC) PDX Models 
A Champions Model Cohort

Advance your hepatocellular carcinoma therapeutic candidates using a tumor bank of rare and meticulously curated PDX models directly established from naïve and pretreated patient tumors.

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

Supporting Advanced Hepatocellular Carcinoma Research

Champions Oncology has developed a cutting-edge cohort of Hepatocellular Carcinoma (HCC) models, offering a comprehensive approach to liver cancer research. Our liver malignancy bank features 9* patient-derived xenograft (PDX) models, established from patient biopsies to preserve original molecular and clinical characteristics while minimizing genetic drift.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Hepatocellular Carcinoma cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access one of the largest banks of HCC models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Includes models pretreated with advanced cancer therapies and those resistant to targeted treatments and the latest immunotherapies, kinase therapies, and more. 
  • Access to highly characterized HCC models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
  • Features models retaining key mutation profiles and clinical cancer characteristics.